Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.53)
# 2,240
Out of 4,714 analysts
22
Total ratings
60%
Success rate
10.89%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.02 | +149.00% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $9.74 | +28.34% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $3.00 | +100.00% | 1 | Aug 12, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $26 → $28 | $26.42 | +5.98% | 1 | Aug 9, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.55 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $2 → $1.25 | $0.53 | +136.56% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.96 | +736.82% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $14.68 | +444.96% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $9.19 | +150.27% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $2.19 | +995.89% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.78 | +112,576.06% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.66 | - | 1 | Sep 27, 2017 |
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.02
Upside: +149.00%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $9.74
Upside: +28.34%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $3.00
Upside: +100.00%
BioLife Solutions
Aug 9, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $26.42
Upside: +5.98%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $2 → $1.25
Current: $0.53
Upside: +136.56%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.96
Upside: +736.82%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $14.68
Upside: +444.96%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $9.19
Upside: +150.27%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $2.19
Upside: +995.89%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.78
Upside: +112,576.06%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.66
Upside: -